Takashi Kawahara

Takashi Kawahara


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in International Journal of Urology
Verified
Journal Article
Open access
YKYuki Kita
Yuki Kita
HOHikari Otsuka
Hikari Otsuka
KIKatsuhiro Ito
Katsuhiro Ito
THTakuto Hara
Takuto Hara
SSSoichiro Shimura
Soichiro Shimura
TGthe Japan Urological Oncology Group
the Japan Urological Oncology Group
Objectives: Immune checkpoint inhibitors and enfortumab vedotin have opened new avenues for sequential treatment strategies for locally advanced/metastatic urothelial carcinoma (la/mUC). In the pre‐enfortumab vedotin era, many patients could not receive third‐line treatment owing to rapid disease progression and poor general status. This study aimed to analyze real‐world sequential treatment practices for la/mUC in Japan, with a focus on patients who do not receive third‐line treatment.Methods: We analyzed data for 1023 la/mUC patients diagnosed between January 2020 and December 2021 at 54 institutions from a Japanese nationwide cohort.Results: At the median follow‐up of 28.5 months, the median overall survival from first‐line initiation for 905 patients who received systemic anticancer treatment was 19.1 months. Among them, 81% and 32% received second‐ and third‐line treatment. Notably, 52% had their treatment terminated before the opportunity for third‐line treatment. Multivariate logistic regression analysis revealed that low performance status (≥1), elevated neutrophil‐to‐lymphocyte ratio (≥3), and low body mass index (<21 kg/m2) at the start of first‐line treatment were independent risk factors for not proceeding to third‐line treatment (p = 0.0024, 0.0069, and 0.0058, respectively). In this cohort, 33% had one of these factors, 36% had two, and 15% had all three.Conclusions: This study highlights the high frequency of factors associated with poor tolerance to anticancer treatment in la/mUC patients. The findings suggest the need to establish optimal sequential treatment strategies, maximizing efficacy within time and tolerance constraints, while concurrently providing strong supportive care, considering immunological and nutritional aspects.

23 April 2022 in International Journal of Urology
Verified
Journal Article
Open access
TKTakashi Kawahara
Takashi Kawahara
KKKoji Kawai
Koji Kawai
TKTakahiro Kojima
Takahiro Kojima
YNYoshiyuki Nagumo
Yoshiyuki Nagumo
SSShotarou Sakka
Shotarou Sakka
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
Objectives: Germ cell tumors are highly susceptible to chemotherapy; however, there is a lack of established treatments for consistently relapsing germ cell tumor. Therefore, in this phase II study, we evaluated the efficacy and safety of nivolumab for relapsed germ cell tumor.Methods: Seventeen adult patients (median age 34 years) with refractory primary germ cell tumor after second‐line or higher chemotherapy were enrolled. Nivolumab was administered over 30 min at 240 mg/body every 2 weeks until disease progression or intolerable adverse event occurrence. The primary endpoint was the overall response rate.Result: We performed a biomarker analysis of programmed death ligand‐1 expression and genomic sequencing. Tumor histology revealed nonseminoma and seminoma in 14 and three patients, respectively. Patients were pretreated with a median of three chemotherapy lines, and three patients received high‐dose chemotherapy. The median number of nivolumab doses was 3 (range 2–46). One patient showed a partial response and three showed stable disease. Responses were durable in one patient with a partial response and one patient with stable disease (median 90 and 68 weeks, respectively). Nivolumab was well‐tolerated, with only two Grade 3 adverse events observed. Programmed death ligand‐1 expression was not associated with objective responses. Genomic sequencing revealed a high tumor mutation burden in a patient with a durable partial response. While a small subset of chemorefractory germ cell tumors may respond to nivolumab, programmed death ligand‐1 is unreliable to measure response.Conclusions: Tumor mutation burden is a potential biomarker for future testing of germ cell tumor response.

2 September 2022 in Cancer Science
Verified
Journal Article
Open access
HOHikari Otsuka
Hikari Otsuka
YKYuki Kita
Yuki Kita
KIKatsuhiro Ito
Katsuhiro Ito
TSTakeshi Sano
Takeshi Sano
JIJunichi Inokuchi
Junichi Inokuchi
TKTakashi Kobayashi
Takashi Kobayashi
To investigate the association between the onset, severity, and type of immune‐related adverse events (irAEs) and the efficacy of pembrolizumab in patients with platinum‐pretreated advanced urothelial carcinoma (UC), we retrospectively collected clinical datasets of 755 patients and conducted landmark analysis. Patients who survived for fewer than 3 months were excluded from the evaluation to reduce the immortal time bias. In total, 620 patients were evaluated, of whom 220 patients (35.5%) experienced grade ≥2 irAEs, including 134 patients with grade 2 irAEs and 86 with grade ≥3 irAEs. Propensity score matching extracted 198 patients with and without grade ≥2 irAEs. The onset of grade ≥2 irAEs was associated with longer median progression‐free survival (PFS) (8.3 months vs. 4.5 months, p = 0.003) and overall survival (OS) (20.4 months vs. 14.3 months, p = 0.031) and a higher objective response rate (ORR) (44.8% vs. 30.2%, p = 0.004). Patients with grade 2 irAEs had significantly better oncological outcomes (PFS, OS, and ORR) than grade ≤1 and ≥3 irAEs. Patients with grade ≥3 irAEs had worse outcomes than grade 2 irAEs. Endocrine and skin irAEs were related with better survival outcomes, and the rate of severities was lower in these categories. In conclusion, the occurrence of irAEs, particularly low‐grade irAEs, was predictive of pembrolizumab efficacy in patients with platinum‐pretreated advanced UC.

1 August 2019 in PLOS ONE
Verified
Journal Article
Open access
TKTakashi Kawahara
Takashi Kawahara
TKTakahiro Kojima
Takahiro Kojima
SKShuya Kandori
Shuya Kandori
MKMasahiro Kurobe
Masahiro Kurobe
TYTakayuki Yoshino
Takayuki Yoshino
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
TP53, a well-known tumor-suppressor gene in bladder carcinogenesis, has a functional single-nucleotide polymorphism on codon 72. The aim of this study was to elucidate the association between TP53 codon 72 polymorphism and somatic mutations in bladder cancer. Germline TP53 codon 72 polymorphism and somatic mutations of 50 cancer-associated genes were analyzed in 103 bladder cancer patients (59 non-muscle-invasive and 44 muscle-invasive), using Taqman genotyping assay and target sequencing, respectively. The expression of FGF-FGFR signaling pathway genes was analyzed by RNA sequencing of frozen tissue. The allele frequency of TP53 codon 72 in our cohort was 37, 42, and 21% for Arg/Arg, Arg/Pro, and Pro/Pro, respectively. Interestingly, the prevalence of FGFR3 mutation was higher in patients with the Arg allele, whereas that of the RAS mutation was higher in patients without the Arg allele. The same association was seen in non-muscle-invasive bladder cancer (NMIBC) patients and no differences were observed in muscle-invasive bladder cancer patients. In NMIBC, FGFR1 expression was higher in patients without the Arg allele and FGFR3 expression was higher in patients with the Arg allele. The germline TP53 codon 72 polymorphism was associated with mutations of FGFR3 or RAS and expression of FGFR1 and FGFR3 in NMIBC. These findings provide new insight into the molecular mechanisms underlying the influence of the genetic background on carcinogenesis in bladder cancer.

6 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
JYJunji Yonese
Junji Yonese
TKTakashi Kawahara
Takashi Kawahara
RMRyuji Matsumoto
Ryuji Matsumoto
HMHideaki Miyake
Hideaki Miyake
SSShigetaka Suekane
Shigetaka Suekane
We evaluated the efficacy and safety of TAS0313, a multi-epitope long peptide vaccine, plus pembrolizumab in post-chemotherapy immune checkpoint inhibitor—naïve patients with locally advanced/metastatic urothelial carcinoma (la/mUC). TAS0313 9 mg was administered subcutaneously followed by pembrolizumab 200 mg on Day 1, and as monotherapy on Day 8 and 15 of Cycles 1 and 2, and Day 1 of subsequent cycles in 21-day cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Biomarkers of response were assessed. In 36 patients enrolled, the ORR was 33.3% (complete response: 7 patients; partial response: 5 patients). Median PFS was 5.0 months; 6- and 12-month progression-free rates were 46.4% and 36.5%, respectively. Median OS was not reached; 6-, 12-, and 24-month OS rates were 83.3%, 72.2%, and 55.1%, respectively. In post hoc analysis, patients with a tumor infiltrating CD8+ lymphocyte (CD8+ TIL) count ≥99 and/or programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥50 and lymphocyte count >1,380 cells/μL had higher ORRs and prolonged PFS versus patients with a CD8+ TIL count <99, PD-L1 CPS <50, and lymphocyte count ≤1,380 cells/μL. Thirty-four (94.4%) patients receiving combination therapy experienced treatment-related adverse events (AE), with pyrexia (n = 15, 41.7%), injection-site reactions (n = 15, 41.7%), injection-site induration (n = 6, 16.7%), and malaise (n = 6, 16.7%) the most common. No grade ≥3 treatment-related AEs occurred in ≥10% of patients. TAS0313 plus pembrolizumab combination therapy showed promising efficacy and manageable safety in la/mUC. Clinical Trial Registration: JapicCTI-183824.

10 March 2026 in International Journal of Urology
Verified
Journal Article
Open access
TATakashige Abe
Takashige Abe
KMKosuke Miyai
Kosuke Miyai
TTToyonori Tsuzuki
Toyonori Tsuzuki
SMSachiyo Murai
Sachiyo Murai
KHKatsuyoshi Hashine
Katsuyoshi Hashine
NSNobuo Shinohara
Nobuo Shinohara
Objectives: Sex cord‐stromal tumors (SCSTs) constitute approximately 5% of testicular malignancies. This investigation aimed to elucidate contemporary therapeutic approaches and clinical outcomes for patients with testicular SCSTs in Japan. Methods: Participating institutions included Japan Clinical Oncology Group facilities, affiliated centers, and institutions with published cases. Clinical data and histopathological findings were compiled. Central pathological review involved representative tissue sections when available. Kaplan–Meier methodology assessed recurrence‐free survival (RFS) and overall survival (OS). Stage I patients were stratified by cumulative pathological risk factors (tumor diameter ≥ 5 cm, necrosis, moderate to severe nuclear atypia, lymphovascular invasion, infiltrative growth, and ≥ 3 mitoses per 10 high‐power fields). Results: Among 116 patients from 66 institutions, 112 met inclusion criteria. Histological distribution included Leydig cell ( n = 54), Sertoli cell ( n = 36), and other variants ( n = 22). Twelve patients presented with metastatic disease; ten received systemic chemotherapy, with 20.8% five‐year OS. Among 91 stage I patients with follow‐up data, eleven developed recurrence. Patients with > 2 risk factors demonstrated significantly inferior RFS compared with those showing ≤ 1 factor (26.4 versus 98.6% at 5 years, p < 0.0001). Surgical intervention predominated in the recurrent cases (81.8%, 9/11), while chemotherapy was administered to 45.5% (5/11), and selected patients achieved prolonged disease control through repeated surgical resection without systemic therapy. OS rates were 90.9% and 50.5% at 5 and 10 years. Conclusions: Patients with synchronous metastatic presentation demonstrated poor survival. Stage I patients with > 2 pathological risk factors showed reduced RFS, with surgical management potentially efficacious for recurrent disease.